Moshe Oren
Weizmann Institute of Science
|
Primary Section: 41, Medical Genetics, Hematology, and Oncology Secondary Section: 22, Cellular and Developmental Biology Membership Type:
International Member
(elected 2019)
|
Biosketch
Moshe Oren has made numerous contributions to the study of the p53 tumor suppressor gene and protein. He was born in Poland and immigrated to Israel in 1950. He received a Master's degree in microbiology from Tel Aviv University, and a PhD degree from the Weizmann Institute, where he worked under Ernest Winocour on the SV40 DNA tumor virus. This was followed by a post-doc with Arnold Levine, co-discoverer of p53, at Princeton University and SUNY Stony Brook. Oren returned to the Weizmann Institute in 1981 as a junior faculty member, and has been there ever since. He served as President of the European Association for Cancer Research (EACR), and is the founding director of the Moross Integrated Cancer Center at the Weizmann Institute. He is a foreign associate of the National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences, and a member of the Israeli Academy of Sciences and Humanities and the Academia Europaea.
Research Interests
The Oren lab is studying two key tumor suppressor pathways: the p53 pathway and the Hippo pathway. Current research aims to address molecular mechanisms that drive tumor initiation and progression, focusing on both genetic and epigenetic processes whose deregulation favors cancer. These studies employ a combination of cell-based models, mouse models, and human cancer data mining.
